{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:38:10Z","timestamp":1789846690536,"version":"4.0.1"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["PO1 CA81403"],"award-info":[{"award-number":["PO1 CA81403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RO1 CA82830"],"award-info":[{"award-number":["RO1 CA82830"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002814","name":"Dougherty Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002814","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001244","name":"Milken Family Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001244","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Evan Dunbar Foundation"},{"name":"Alex Lemonade Stand"},{"DOI":"10.13039\/100002730","name":"Children's Neuroblastoma Cancer Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002730","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Neuroblastoma Children's Cancer Society"},{"name":"Douglas Michael Fuller Foundation"},{"name":"Because of Ezra Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1002\/pbc.25994","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T20:56:01Z","timestamp":1461099361000},"page":"1349-1356","source":"Crossref","is-referenced-by-count":93,"title":["A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent\/Refractory High-Risk Neuroblastoma"],"prefix":"10.1002","volume":"63","author":[{"given":"Judith G.","family":"Villablanca","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Volchenboum","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of Chicago Comprehensive Cancer Center; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwangeui","family":"Cho","sequence":"additional","affiliation":[{"name":"Cancer Center and Departments of Cell Biology & Biochemistry, Pediatrics, and Medicine; Texas Tech University Health Sciences Center School of Medicine; Lubbock Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Kang","sequence":"additional","affiliation":[{"name":"Cancer Center and Departments of Cell Biology & Biochemistry, Pediatrics, and Medicine; Texas Tech University Health Sciences Center School of Medicine; Lubbock Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Cohn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of Chicago Comprehensive Cancer Center; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarke P.","family":"Anderson","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center; Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Marachelian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Groshen","sequence":"additional","affiliation":[{"name":"Department of Preventative Medicine Statistics, Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice","family":"Tsao-Wei","sequence":"additional","affiliation":[{"name":"Department of Preventative Medicine Statistics, Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Matthay","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of California San Francisco; San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Maris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Hasenauer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett","family":"Czarnecki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Radiology; Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Goodarzian","sequence":"additional","affiliation":[{"name":"Department of Radiology; Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiro","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Pathology and The Saban Research Institute, Children's Hospital Los Angeles and Keck School of Medicine; University of Southern California; Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Patrick","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Cancer Center and Departments of Cell Biology & Biochemistry, Pediatrics, and Medicine; Texas Tech University Health Sciences Center School of Medicine; Lubbock Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"10.1002\/pbc.25994-BIB0001|pbc25994-cit-0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0002|pbc25994-cit-0002","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.25994-BIB0003|pbc25994-cit-0003","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1200\/JCO.1991.9.6.962","article-title":"Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases","volume":"9","author":"Dini","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0004|pbc25994-cit-0004","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.25994-BIB0005|pbc25994-cit-0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.20219","article-title":"High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group","volume":"44","author":"Pritchard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25994-BIB0006|pbc25994-cit-0006","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-2952(83)90671-8","article-title":"Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content","volume":"32","author":"Suzukake","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0007|pbc25994-cit-0007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-2952(82)90249-0","article-title":"Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity","volume":"31","author":"Suzukake","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0008|pbc25994-cit-0008","first-page":"1","article-title":"Evolution of glutathione metabolism","volume":"64","author":"Fahey","year":"1991","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1002\/pbc.25994-BIB0009|pbc25994-cit-0009","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/S0021-9258(18)35980-5","article-title":"Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)","volume":"254","author":"Griffith","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1002\/pbc.25994-BIB0010|pbc25994-cit-0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0021-9258(17)34188-1","article-title":"Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n-propyl homocysteine sulfoximine), a selective inhibitor of gamma-glutamylcysteine synthetase","volume":"254","author":"Griffith","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1002\/pbc.25994-BIB0011|pbc25994-cit-0011","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1016\/S0021-9258(18)33504-X","article-title":"Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis","volume":"257","author":"Griffith","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1002\/pbc.25994-BIB0012|pbc25994-cit-0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-2952(84)90245-4","article-title":"Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard","volume":"33","author":"Somfai Relle","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0013|pbc25994-cit-0013","first-page":"5427","article-title":"Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion","volume":"44","author":"Green","year":"1984","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25994-BIB0014|pbc25994-cit-0014","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/0006-2952(85)90551-9","article-title":"Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion","volume":"34","author":"Hamilton","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0015|pbc25994-cit-0015","first-page":"2110","article-title":"Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine","volume":"45","author":"Louie","year":"1985","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25994-BIB0016|pbc25994-cit-0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-2952(87)90392-3","article-title":"Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione","volume":"36","author":"Ozols","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0017|pbc25994-cit-0017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CAD.0000000000000192","article-title":"Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells","volume":"26","author":"Ongaro","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1002\/pbc.25994-BIB0018|pbc25994-cit-0018","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00043426-200111000-00007","article-title":"Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line","volume":"23","author":"Anderson","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.25994-BIB0019|pbc25994-cit-0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.bmt.1703605","article-title":"Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy","volume":"30","author":"Anderson","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/pbc.25994-BIB0020|pbc25994-cit-0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/excr.1998.4303","article-title":"Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis","volume":"246","author":"Anderson","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1002\/pbc.25994-BIB0021|pbc25994-cit-0021","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0959-8049(97)00203-7","article-title":"Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines","volume":"33","author":"Anderson","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1002\/pbc.25994-BIB0022|pbc25994-cit-0022","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bjc.1987.127","article-title":"Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line","volume":"55","author":"Jordan","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1002\/pbc.25994-BIB0023|pbc25994-cit-0023","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.1993.484","article-title":"In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy","volume":"68","author":"Siemann","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1002\/pbc.25994-BIB0024|pbc25994-cit-0024","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/1523-1747.ep12616629","article-title":"Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan","volume":"99","author":"Prezioso","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1002\/pbc.25994-BIB0025|pbc25994-cit-0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0749.1990.tb00322.x","article-title":"Effects of tyrosinase activity on the cytotoxicity of 3,4- dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells","volume":"3","author":"Prezioso","year":"1990","journal-title":"Pigment Cell Res"},{"key":"10.1002\/pbc.25994-BIB0026|pbc25994-cit-0026","first-page":"1520","article-title":"Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine","volume":"63","author":"Yang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25994-BIB0027|pbc25994-cit-0027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yexcr.2015.03.024","article-title":"Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration","volume":"334","author":"Sheard","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1002\/pbc.25994-BIB0028|pbc25994-cit-0028","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/81.7.524","article-title":"Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion","volume":"81","author":"Friedman","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.25994-BIB0029|pbc25994-cit-0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00684950","article-title":"Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine","volume":"28","author":"Skapek","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0030|pbc25994-cit-0030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.1994.12.1.194","article-title":"Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione","volume":"12","author":"Bailey","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0031|pbc25994-cit-0031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1200\/JCO.1996.14.1.249","article-title":"Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer","volume":"14","author":"O'Dwyer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0032|pbc25994-cit-0032","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/jnci\/89.23.1789","article-title":"Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan","volume":"89","author":"Bailey","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.25994-BIB0033|pbc25994-cit-0033","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/pbc.25594","article-title":"Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma","volume":"62","author":"Anderson","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25994-BIB0034|pbc25994-cit-0034","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.25994-BIB0035|pbc25994-cit-0035","first-page":"673","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma","volume":"21","author":"Yanik","year":"2015","journal-title":"A New Approaches to Neuroblastoma Therapy (NANT) phase II study. Biol Blood Marrow Transplant"},{"key":"10.1002\/pbc.25994-BIB0036|pbc25994-cit-0036","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pbc.20777","article-title":"Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma","volume":"47","author":"Messina","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25994-BIB0037|pbc25994-cit-0037","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst"},{"key":"10.1002\/pbc.25994-BIB0038|pbc25994-cit-0038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2125.2007.02862.x","article-title":"Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients","volume":"64","author":"Nath","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0039|pbc25994-cit-0039","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2125.2004.02319.x","article-title":"Melphalan pharmacokinetics in children with malignant disease: Influence of body weight, renal function, carboplatin therapy and total body irradiation","volume":"59","author":"Nath","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0040|pbc25994-cit-0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00273524","article-title":"High-dose melphalan dosage adjustment: Possibility of using a test-dose","volume":"23","author":"Tranchand","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0041|pbc25994-cit-0041","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00293997","article-title":"Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis","volume":"16","author":"Ardiet","year":"1986","journal-title":"Report in 26 cases. Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0042|pbc25994-cit-0042","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","article-title":"Pharmacokinetics of high-dose melphalan in children and adults","volume":"16","author":"Gouyette","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25994-BIB0043|pbc25994-cit-0043","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","article-title":"Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study","volume":"29","author":"Bagatell","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0044|pbc25994-cit-0044","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid","volume":"341","author":"Matthay","year":"1999","journal-title":"Children's Cancer Group. N Engl J Med"},{"issue":"Suppl 2","key":"10.1002\/pbc.25994-BIB0045|pbc25994-cit-0045","article-title":"Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1\/SIOPEN trial","volume":"29","author":"Ladenstein","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25994-BIB0046|pbc25994-cit-0046","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1038\/bcj.2014.45","article-title":"The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma","volume":"4","author":"Tagde","year":"2014","journal-title":"Blood Cancer J"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25994","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25994","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25994\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T04:07:06Z","timestamp":1655525226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25994"}},"subtitle":["Phase I BSO-Melphalan in Neuroblastoma"],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25994","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}